$1.74—Stale · unknown old
SET • Last print unknown ago
$1.74—Stale · unknown old
JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. is a key player in the Thai pharmaceutical sector, focusing on the production of generic and branded medications. The company benefits from its strategic location in Thailand, which serves as a hub for Southeast Asian markets, and its established relationships with healthcare providers and distributors.
JSP generates revenue primarily through the sale of generic and branded pharmaceuticals, leveraging its cost-effective production capabilities and regulatory compliance to maintain competitive pricing. The company also engages in contract manufacturing, providing additional revenue streams and enhancing operational efficiency.
Regulatory approvals for new drug formulations
Changes in healthcare policies affecting drug pricing
Market expansion into neighboring Southeast Asian countries
Fluctuations in raw material costs impacting margins
Regulatory changes in pharmaceutical pricing and approvals
Technological advancements in drug development that could outpace JSP's capabilities
Intense competition from both local and international pharmaceutical companies
Potential for price wars in generic drug markets
Moderate debt levels could become a concern if cash flow does not improve
Negative free cash flow may limit future investment opportunities
moderate - JSP's performance is somewhat tied to overall healthcare spending, which can be influenced by GDP growth and consumer spending patterns.
Rising interest rates could increase financing costs for JSP, affecting capital expenditures and potentially slowing down expansion plans. However, the company's low debt levels mitigate this risk.
minimal - JSP is not heavily reliant on credit for its operations, maintaining a conservative debt-to-equity ratio.
growth - JSP's strong revenue and net income growth rates attract investors looking for expanding companies in the healthcare sector.
moderate - The stock has shown some volatility, with a 1-year return of 8.6%, indicating a balanced risk-reward profile.